Skip to main content
Tilray Brands, Inc. logo

Tilray Brands, Inc. — Investor Relations & Filings

Ticker · TLRY ISIN · US88688T2096 LEI · 549300Y4V60733TO1478 TSX Manufacturing
Open in API
Filings indexed 397 across all filing types
Latest filing 2021-08-19 Regulatory Filings
Country US United States of America
Listing TSX TLRY

About Tilray Brands, Inc.

https://www.tilray.com/

Tilray Brands, Inc. is a global consumer packaged goods and cannabis-lifestyle company focused on enhancing wellbeing through innovative products. The company operates a diversified portfolio encompassing pharmaceutical, medical, and recreational cannabis, alongside consumer packaged goods, including beverages. Tilray is a leading producer of GMP-certified medical cannabis and holds the top market share position in the Canadian recreational cannabis sector. Leveraging advanced greenhouse cultivation and an extensive global supply chain, Tilray distributes a wide range of products—such as whole flower, vapes, and pre-rolls—across key markets in Canada, Europe, the United States, Australia, and Latin America.

Recent filings

Filing Released Lang Actions
Notice.pdf
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated May 21, 2021, by Tilray, Inc. It reports the dismissal of the previous independent registered public accounting firm (Deloitte) and the appointment of a new one (PwC). It discusses details about audit opinions, reportable events, and includes a letter from Deloitte agreeing with the statements made. The document is a current report on a change in the company's certifying accountant, which is a regulatory announcement about management and auditor changes. It does not contain full financial statements or detailed financial analysis, so it is not an Annual Report (10-K) or Audit Report (AR). It is not a report publication announcement since it contains substantive information about the change. The best fitting category is Regulatory Filings (RNS), as it is a general regulatory announcement about auditor changes and related disclosures.
2021-08-19 English
Other.pdf
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a communication from the CEO of Tilray encouraging shareholders to vote in favor of a share proposal related to authorizing more shares to facilitate a transaction involving MedMen securities. It includes a phone message and an email message urging shareholders to vote and provides details about the transaction and its strategic benefits. There is no detailed financial data, no full report, and no formal announcement of voting results. The document is clearly a solicitation for votes related to a shareholder proposal, which aligns with Proxy Solicitation & Information Statement filings. The document length is short (3137 characters), and it is not a report publication announcement or a regulatory filing. Therefore, the best classification is Proxy Solicitation & Information Statement (PSI).
2021-08-18 English
Other.pdf
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement about Tilray acquiring a majority position in amended convertible notes of MedMen, including terms of the transaction, strategic rationale, and related party transaction disclosures. It discusses financing activities such as acquisition of convertible notes, amendment and extension of debt maturity, issuance of shares, and private placement. There is no presentation of financial statements or quarterly/yearly financial results, nor is it a transcript or governance report. The content focuses on capital structure changes and financing arrangements. Therefore, this document fits best under the category of Capital/Financing Update (CAP). The document length and detail confirm it is not a brief announcement or a simple regulatory filing, but a substantive financing update.
2021-08-18 English
Material change report - English.pdf
Capital/Financing Update Classification · 100% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content describes Tilray's acquisition of a majority position in MedMen's convertible notes, details of the transaction, amendments to the notes, and related strategic information. It includes specifics about securities transactions, stockholder approval requirements, and amendments to financial instruments. This is a clear example of a Capital/Financing Update as it relates to fundraising and capital structure changes. The document is lengthy (15,000 characters) and contains detailed transaction information, not just an announcement or summary, so it is not a Report Publication Announcement or Regulatory Filing. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2021-08-18 English
Other.pdf
Regulatory Filings Classification · 95% confidence The document is a certification letter from the Chief Financial Officer regarding the interim financial report and interim MD&A for the period ended June 30, 2021. It explicitly states it is a certification of interim filings, confirming the accuracy and fair presentation of the interim financial report. The document does not contain actual financial data or substantive financial analysis but serves as an officer attestation. According to the Certification Rule, such documents should be classified as Regulatory Filings (RNS) rather than as the interim report itself (IR). The document length is 3348 characters, which is relatively short and consistent with a certification letter rather than a full interim report.
2021-08-09 English
Other.pdf
Regulatory Filings
2021-08-05 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.